Background: Inflammation plays a key role in the pathogenesis of type 2 diabetes (T2D) and the associated cardiovascular complications. High-sensitivity C-reactive protein (hsCRP) is a widely used marker of systemic inflammation as well as a predictor of cardiovascular risk. Objective: There is increasing evidence that glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, may have effects on hsCRP levels, independent of their effects on glycemic control and body weight loss. This purpose of our study is to explore the effect of semaglutide on hsCRP levels in patients with type 2 diabetes. Additionally, we aimed to determine whether the observed effect of semaglutide on hsCRP is fully mediated by changes in HbA1c and body weight, or whether there is a direct effect suggesting the presence of an independent anti-inflammatory mechanism. Methods: The study included 70 outpatients with diagnosed type 2 diabetes undergoing therapy with metformin and/or a sulfonylurea. Semaglutide was added to the existing therapeutic regimen. All participants were followed up after a 6-month a period. At the beginning and at the end of the study, the hsCRP values, some selected indicators of glycemic control, and the anthropometric measurements were recorded. Results: The mean hsCRP value at baseline was 4.90 ± 1.21 mg/L, while after six-month therapy, it dropped to 2.23 ± 2.21 mg/L. Conclusions: The results of the analysis have a good potential to contribute to a better understanding of the pleiotropic effects of GLP-1 RAs and support the hypothesis of a direct anti-inflammatory role of semaglutide, which could have clinical significance in the context of cardiometabolic risk management in patients with type 2 diabetes.
Inflammation plays a key role in the pathogenesis of type 2 diabetes (T2D) and the associated cardiovascular complication. High-sensitivity C-reactive protein (hsCRP) is a widely used marker of systemic inflammation as well as a predictor of cardiovascular risk. There is increasing evidence that glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, may have effect on hsCRP levels, independent of their effects on glycemic control and body weight loss. This purpose of our study is to explore the effect of semaglutide on hsCRP levels in patients with type 2 diabetes. Additionally, we aimed to determine whether the observed effect of semaglutide on hsCRP is fully mediated by changes in HbA1c and body weight, or whether there is a direct effect suggesting the presence of an independent anti-inflammatory mechanism. The study included 66 outpatients with diagnosed type 2 diabetes undergoing therapy with metformin and/or a sulfonylurea. Semaglutide was added to the existing therapeutic regimen. All participants were followed up for 6 months period. Respectively, at the beginning and at the end of the study, the hsCRP values, some selected indicators of glycemic control as well as the anthropometric measurements were recorded. The mean hsCRP value at baseline was 4.90±1.21 mg/L, while after six-month therapy it dropped to 2.23±2.21 mg/L. The results of the analysis have a good potential to contribute to better understanding of the pleiotropic effects of GLP-1 RAs and support the hypothesis of a direct anti-inflammatory role of semaglutide, which could have clinical significance in the context of cardiometabolic risk management in patients with type 2 diabetes.
Introduction: Remogliflozin is a sodium–glucose cotransporter-2 inhibitor used for type 2 diabetes mellitus (T2DM), but its overall efficacy and safety remain fragmented. This updated systematic review and meta-analysis evaluated the efficacy and safety of remogliflozin using evidence exclusively from randomized controlled trials (RCTs). Methods: PubMed; Scopus; and the Cochrane Library were searched from inception to 15 July 2026 for RCTs lasting at least 12 weeks that compared remogliflozin or a remogliflozin-containing regimen with placebo; usual care; or another glucose-lowering treatment in adults with T2DM (PROSPERO: CRD420261462138). Risk ratios (RRs) were calculated using the Mantel–Haenszel method and mean differences (MDs) using the inverse-variance method. Random-effects models with restricted maximum-likelihood estimation and Hartung–Knapp adjustment were applied. Heterogeneity was assessed using I2 and Cochran’s Q test. Results: Nine RCTs involving 1731 participants were included, of whom 906 (52.3%) received remogliflozin or a remogliflozin-containing regimen. Across heterogeneous comparator regimens, remogliflozin-containing treatment strategies were associated with lower HbA1c (MD −0.40 percentage points; 95% CI −0.63 to −0.16; I2 = 59.9%; p < 0.01) and body weight (MD −2.15 kg; 95% CI −3.26 to −1.03; I2 = 56.5%; p < 0.01). No statistically significant differences were detected for fasting plasma glucose (MD −6.84 mg/dL; 95% CI −16.07 to 2.38; I2 = 59.4%; p = 0.150), total adverse events (RR 1.16; 95% CI 0.93–1.43; I2 = 0%; p = 0.155), or hypoglycaemia (RR 0.89; 95% CI 0.28–2.81; I2 = 0%; p = 0.696); however, the safety estimates, particularly for hypoglycaemia, were imprecise. Conclusions: Across heterogeneous randomized comparisons, remogliflozin-containing treatment strategies were associated with modest reductions in HbA1c and body weight, whereas the effect on fasting plasma glucose remained inconclusive. The available evidence was insufficient to establish whether total adverse events or hypoglycaemia differed between treatment groups because of the small evidence base, short follow-up, sparse events, and imprecise estimates.